8-KLeadership ChangesRegulation FDExhibits & Filings

CVS HEALTH Corp 8-K Report, Executive Changes (Aug 17, 2026)

Filed August 17, 2026For Securities:CVS

Summary

CVS Health Corporation (CVS) filed an 8-K report on August 17, 2026, primarily announcing changes to its Board of Directors. Larry M. Robbins has resigned from the Board, effective immediately, with the company stating this was not due to any disagreements. The report also details the appointment of Teresa Heitsenrether to the Board, effective November 18, 2026. Ms. Heitsenrether brings significant experience from JPMorgan Chase, where she serves as Executive Vice President and Chief Data & Analytics Officer. Her appointment is expected to enhance the Board's expertise, particularly in areas related to data and analytics. The company has confirmed Ms. Heitsenrether meets independence standards and her compensation will align with existing non-employee director policies, subject to proration for her start date. Investors should note that her appointment is purely a board position, with no prior arrangements or related party transactions disclosed.

Key Highlights

  • 1Larry M. Robbins has resigned from the CVS Health Board of Directors, effective August 13, 2026.
  • 2The resignation of Mr. Robbins was stated to be amicable and not the result of any disagreements with the Company.
  • 3Teresa Heitsenrether has been appointed to the Board of Directors, with her term commencing November 18, 2026.
  • 4Ms. Heitsenrether is a seasoned executive, currently serving as EVP and Chief Data & Analytics Officer at JPMorgan Chase.
  • 5The appointment of Ms. Heitsenrether is considered an independent director under NYSE and Company guidelines.
  • 6Ms. Heitsenrether's compensation will be in line with other non-employee directors, adjusted for her effective start date.
  • 7The company issued a press release on August 17, 2026, to announce these board changes.

Frequently Asked Questions

According to the filing, Larry M. Robbins' resignation was not due to any disagreement with CVS Health Corporation on any matter relating to the operations, policies, or practices of the Company.

Ms. Heitsenrether brings extensive experience from her role as Executive Vice President and Chief Data & Analytics Officer at JPMorgan Chase, where she is also a member of the Operating Committee. Her background includes leadership roles in Securities Services and Prime Brokerage & Equity Financing.

Teresa Heitsenrether's appointment to the Board of Directors is effective November 18, 2026.

No, Ms. Heitsenrether's compensation for her service as a non-employee director will be consistent with that of the Company's other non-employee directors. It will be prorated to reflect her November 18, 2026, start date. Her compensation practices are detailed in the Company's annual proxy statement.